$AVCO Avalon GloboCare Adds CAR-NK Cell Therapies
Post# of 103076
(Total Views: 214)
Posted On: 02/17/2022 9:02:30 AM
$AVCO Avalon GloboCare Adds CAR-NK Cell Therapies To Expand Cellular Immuno-Oncology Platform
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
AVA-011 is currently at the IND-enabling process development stage.
Related: Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights.
The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.
Price Action: AVCO shares are down 1.18% at $0.87 during the market session on the last check Monday.
See more from Benzinga
UNITY Biotech Stock Jumps On Additional Data From UBX1325 Trial In Vascular Eye Disease
Pardes Biosciences Shares Early Data From COVID-19 Study
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
https://finance.yahoo.com/news/avalon-globoca...21173.html
Avalon GloboCare Corp (NASDAQ: AVCO) is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies.
Avalon is leveraging its mRNA-based FLASH-CAR platform to develop autologous and universal CAR-NK technology and cellular therapies for the potential treatment of hematologic malignancies and solid tumors.
The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate.
AVA-011 is currently at the IND-enabling process development stage.
Related: Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights.
The platform uses next-generation CAR technology to modify patients' T or universal-donor NK cells using a ribonucleic acid (RNA)-based platform rather than a viral vector, allowing for more rapid and lower-cost bio-manufacturing the cell therapy products.
Price Action: AVCO shares are down 1.18% at $0.87 during the market session on the last check Monday.
See more from Benzinga
UNITY Biotech Stock Jumps On Additional Data From UBX1325 Trial In Vascular Eye Disease
Pardes Biosciences Shares Early Data From COVID-19 Study
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
https://finance.yahoo.com/news/avalon-globoca...21173.html
(0)
(0)Scroll down for more posts ▼